Top

Journal of Assisted Reproduction and Genetics

Published in:

01-08-2008 | ASSISTED REPRODUCTION

Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study

Authors: Rafal Kurzawa, Przemyslaw Ciepiela, Tomasz Baczkowski, Krzysztof Safranow, Pawel Brelik

Published in: Journal of Assisted Reproduction and Genetics | Issue 8/2008

Abstract

Purpose

Embryological and clinical efficacy of gonadotropin-releasing hormone (GnRH) antagonist and agonist stimulation protocols in non-obese women with polycystic ovarian syndrome (PCOS) were compared.

Methods

A prospective randomized study. Setting: Medical University Hospital. Patients: 70 infertile PCOS patients; 33 in GnRH antagonist and 37 in GnRH agonist group.

Results

Similar mature metaphase II oocyte rate (76% vs. 76%) was observed in both protocols. Optimal pronuclear morphology zygotes dominated in both groups (64% vs. 66%). Transferred embryo quality did not differ in both protocols. No significant differences between both protocols were found in delivery rate (p = 0.481), pregnancy rate (p = 0.810), multiple pregnancy rate (p = 0.501), miscarriage rate (p = 0.154), fertilization rate (p = 0.388) and implantation rate (p = 1.000). Duration of stimulation and total follicle-stimulating hormone (FSH) dose were significantly lower in GnRH antagonist protocol (p = 0.0005).

Conclusions

GnRH antagonist and agonist protocols in non-obese PCOS patients yield similar embryological and clinical outcomes. Shorter duration of treatment and lower FSH requirement in GnRH antagonist group may be financially beneficial and therefore attractive for patients.

Asuncion M, Calvo RM, San Millan JL. A prospective study of the prevalence of the polycystic ovary in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434–8. doi:10.1210/jc.85.7.2434.PubMedCrossRef

Knochenhauer ES, Key TJ, Kahsar-Miller M. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States; a prospective study. J Clin Endocrinol Metab 1998;83:3078–82. doi:10.1210/jc.83.9.3078.PubMedCrossRef

Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 2008;23:462–77. doi:10.1093/humrep/dem426.CrossRef

Homburg R. Management of infertility and prevention of ovarian hyperstimulation in women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18:773–88. doi:10.1016/j.bpobgyn.2004.05.006.PubMedCrossRef

Akagbosu FT. The use of GnRH agonists and antagonists in infertility. In: Brinsden PR, editor. A textbook of in vitro fertilization and assisted reproduction. New York, USA: Partheon; 1999. p. 83–9.

Moghissi KS. A clinician’s guide to use of gonadotropin-releasing hormone analogs in women. Medscape Womens Health 2000;5:5.PubMed

Reissmann T, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, Schally AV. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility. Hum Reprod 1995;10:1974–81.PubMed

Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006;12:651–71. doi:10.1093/humupd/dml038.PubMedCrossRef

Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD001750. doi:10.1002/14651858.CD001750.pub2

10.

Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane Review. Reprod Biomed Online 2007;14:640–9.PubMedCrossRef

11.

Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online 2006;13:628–38.PubMedCrossRef

12.

Fedorcsák P, Dale PO, Storeng R, Tanbo T, Abyholm T. The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Hum Reprod 2001;16:1086–91. doi:10.1093/humrep/16.6.1086.PubMedCrossRef

13.

Fedorcsák P, Dale PO, Storeng R, Ertzeid G, Bjercke S, Oldereid N, et al. Impact of overweight and underweight on assisted reproduction treatment. Hum Reprod 2004;19:2523–8. doi:10.1093/humrep/deh485.PubMedCrossRef

14.

Wittemer C, Ohl J, Bailly M, Bettahar-Lebugle K, Nisand I. Does body mass index of infertile women have an impact on IVF procedure and outcome? J Assist Reprod Genet 2000;17:547–52. doi:10.1023/A:1026477628723.PubMedCrossRef

15.

Bellver J, Melo M, Bosch E, Serra V, Remohí J, Pellicer A. Obesity and poor reproductive outcome: the potential role of the endometrium. Fertil Steril 2007;88:446–51. doi:10.1016/j.fertnstert.2006.11.162.PubMedCrossRef

16.

Hillier SG. Gonadotropic control of ovarian follicular growth and development. Mol Cell Endocrinol 2001;179:36–46. doi:10.1016/S0303-7207(01)00469-5.CrossRef

17.

Fauser BC, Van Heusdon AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 1997;18:71–106. doi:10.1210/er.18.1.71.PubMedCrossRef

18.

Scheele F, Hompes PG, Van der Meer M, Schoute E, Schoemaker J. The relationship between follicle-stimulating hormone dose and level and its relevance for ovulation induction with adjuvant gonadotropin-releasing hormone-agonist treatment. Fertil Steril 1993;60:620–5.PubMed

19.

Laven JS, Imani B, Eijkemans MJ, Fauser BC. New approaches to PCOS and other forms of anovulation. Obstet Gynecol Surv 2002;57:755–67. doi:10.1097/00006254-200211000-00022.PubMedCrossRef

20.

Taylor AE, McCourt B, Martin K, Anderson EJ, Adams J, Schoebfeld D. Determinants of abnormal gonadotropin secretion in clinically defined women with PCOS. J Clin Endocrinol Metab 1997;82:2248–56. doi:10.1210/jc.82.7.2248.PubMedCrossRef

21.

Yoshimura Y, Wallach EE. Studies of the mechanism(s) of mammalian ovulation. Fertil Steril 1987;47:22–34.PubMed

22.

Balen AH, Tan SL, MacDougall J, Jacobs HS. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Hum Reprod 1993;8:959–64.PubMed

23.

Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab 1999;84:1617–22. doi:10.1210/jc.84.5.1617.PubMedCrossRef

24.

Nardo LG, Rai R, Backos M, El Gaddal S, Regan L. High serum luteinizing hormone and testosterone concentrations do not predict pregnancy outcome in women with recurrent miscarriage. Fertil Steril 2002;77:348–52. doi:10.1016/S0015-0282(01)02995-8.PubMedCrossRef

25.

Pagán YL, Srouji SS, Jimenez Y, Emerson A, Gill S, Hall JE. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions. J Clin Endocrinol Metab 2006;91:1309–16. doi:10.1210/jc.2005-2099.PubMedCrossRef

26.

Arroyo A, Laughlin GA, Morales AJ, Yen SS. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab 1997;82:3728–33. doi:10.1210/jc.82.11.3728.PubMedCrossRef

27.

World Health Organization. Manual for standardized investigation and diagnosis of the infertile couple. Melbourne: Cambridge University Press; 1993.

28.

Kruger TF, Acosta AA, Simmons KF, Swanson RJ, Matta JF, Oehninger S. Predictive value of abnormal sperm morphology in in vitro fertilization. Fertil Steril 1988;49:112–7.PubMed

29.

Sakkas D, Shoukir Y, Chardonnens D, Bianchi PG, Campana A. Early cleavage of human embryos to the two-cell stage after intracytoplasmic sperm injection as an indicator of embryo viability. Hum Reprod 1998;13:182–7. doi:10.1093/humrep/13.1.182.PubMedCrossRef

30.

Tesarik J, Junca AM, Hazout A, Aubriot FX, Nathan C, Cohen-Bacrie P, et al. Embryos with high implantation potential after intracytoplasmic sperm injection can be recognized by a simple, non-invasive examination of pronuclear morphology. Hum Reprod 2000;15:1396–9. doi:10.1093/humrep/15.6.1396.PubMedCrossRef

31.

Scott L, Alvero R, Leondires M, Miller B. The morphology of human pronuclear embryos is positively related to blastocyst development and implantation. Hum Reprod 2000;15:2394–403. doi:10.1093/humrep/15.11.2394.PubMedCrossRef

32.

Baczkowski T, Kurzawa R, Glabowski W. Methods of embryo scoring in in vitro fertilization. Reprod Biol 2004;4:5–22.PubMed

33.

Practice Committee of the Society for Assisted Reproductive Technology, Practice Committee of the American Society for Reproductive Medicine. Guidelines on number of embryos transferred. Fertil Steril 2006;86:S51–2.

34.

Balen AH, Tan SL, Jacobs HS. Hypersecretion of luteinizing hormone: a significant cause of infertility and miscarriage. Br J Obstet Gynaecol 1993;100:1082–9.PubMed

35.

Homburg R. In vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome. Fertil Steril 1993;5:858–63.

36.

Ciepiela P, Baczkowski T, Brelik P, Antonowicz A, Safranow K, Kurzawa R. Biotechnological and clinical outcome of in vitro fertilization in non-obese patients with polycystic ovarian syndrome. Folia Histochem Cytobiol 2007;45:S65–71.PubMed

37.

Ashrafi M, Moini A, Mohammadzadeh A, Ezabadi Z, Zafarani F, Baghestani AR. Comparative study of GnRH antagonist and GnRH agonist in PCO patients undergoing IVF/ICSI cycles. Iranian J Reprod Med 2005;13:14–8.

38.

Bahceci M, Ulug U, Ben-Shlomo I, Erden HF, Akman MA. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. J Reprod Med 2005;50:84–90.PubMed

39.

Hwang JL, Seow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, Wu Gj, Huang SC, Chen CY, Chen PH, Tzeng CR. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study. Hum Reprod 2004;19:1993–2000. doi:10.1093/humrep/deh375.PubMedCrossRef

40.

Kim CH, Lee YJ, Hong SH. Efficiency of a GnRH antagonists during early and late ovarian hyperstimulation period in women with polycystic ovary syndrome undergoing IVF-ET. Hum Reprod 2004;19:105–9.

41.

Martin KA, Hall JE, Adams J, Crowley WF. Comparison of exogenous gonadotropins and pulsatile GnRH for induction of ovulation hypogonadotropic amenorrhea. J Clin Endocrinol Metab 1993;77:125–9. doi:10.1210/jc.77.1.125.PubMedCrossRef

42.

Homburg R, Levy T, Ben-Rafael Z. A comparative prospective study of conventional regimen with chronic low-dose administration of follicle stimulating hormone for anovulation associated with polycystic ovary syndrome. Fertil Steril 1995;63:729–33.PubMed

43.

Nyboe A, Goossens V, Gianaroli L, Felberbaum R, de Mouzon J, Nygren KG. Assisted reproductive technology in Europe, 2003. Results generated from European registers by ESHRE. Hum Reprod 2007;22:1513–25. doi:10.1093/humrep/dem053.CrossRef

44.

Wright VC, Chang J, Jeng G, Chen M, Macaluso M. Centers for Disease Control and Prevention. Assisted reproductive technology surveillance — United States, 2004. MMWR Surveill Summ 2007;56:1–22.PubMed

45.

Filicori M. The role of luteinizing hormone in folliculogenesis and ovulation induction. Fertil Steril 1999;71:405–14. doi:10.1016/S0015-0282(98)00482-8.PubMedCrossRef

46.

Schoot DC, Harlin J, Shoham Z, Mannaerts BM, Lahlou N, Bouchard P. Recombinant human follicle-stimulating hormone and ovarian response in gonadotropin-deficient women. Hum Reprod 1994;9:1237–42.PubMed

47.

Ludwig M, Finas DF, al-Hasani S. Oocyte quality and treatment outcome in intracytoplasmic sperm injection cycles of polycystic ovarian syndrome patients. Hum Reprod 1999;14:354–8. doi:10.1093/humrep/14.2.354.PubMedCrossRef

48.

Okon MA, Laird SM, Tuckerman EM, Li TC. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fertil Steril 1998;69:682–90. doi:10.1016/S0015-0282(98)00007-7.PubMedCrossRef

49.

Bjercke S, Fedorcsak P, Abyholm T, Storeng R, Ertzeid G, Oldereid N, et al. IVF/ICSI outcome and serum LH concentration on day 1 of ovarian stimulation with recombinant FSH under pituitary suppression. Hum Reprod 2005;20:2441–7. doi:10.1093/humrep/dei101.PubMedCrossRef

50.

Noci I, Maggi M, Fuzzi B, Biagiotti R, Ricci F, Marchionni M. Effects of low day 3 luteinizing hormone levels on in vitro fertilization treatment outcome. Gynecol Endocrinol 2000;14:321–6.PubMedCrossRef

51.

Cabrera RA, Stadtmauer L, Mayer JF, Gibbons WE, Oehninger S. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone. Fertil Steril 2005;83:42–8. doi:10.1016/j.fertnstert.2004.06.050.PubMedCrossRef

52.

Huirne JA, van Loenen AC, Schats R, McDonnell J, Hompes PG, Schoemaker J, et al. Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy. Hum Reprod 2005;20:359–67. doi:10.1093/humrep/deh601.PubMedCrossRef

53.

Liu SY, Han JL, Peng XD, Dong X, Xu J, Yan JM. Effect of midfollicular luteinizing hormone levels on ovarian response and pregnancy outcome in patients undergoing in vitro fertilization in a short-term protocol. Fertil Steril 2005;83:1043–6. doi:10.1016/j.fertnstert.2004.12.015.PubMedCrossRef

54.

Penarrubia J, Fabregues F, Creus M, Manau D, Casamitjana R, Guimera M. LH serum levels during ovarian stimulation as predictors of ovarian response and assisted reproduction outcome in down-regulated women stimulated with recombinant FSH. Hum Reprod 2003;18:2689–97. doi:10.1093/humrep/deg506.PubMedCrossRef

55.

Lainas TG, Petsas GK, Zorzovilis IZ, Iliadis GS, Kolibianakis EM. Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development. Hum Reprod 2007;22:1540–6. doi:10.1093/humrep/dem033.PubMedCrossRef

56.

Fauser CJM, Devroey P. Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertil Steril 2005;83:1607–11. doi:10.1016/j.fertnstert.2005.02.011.PubMedCrossRef

Title: Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study
Authors: Rafal Kurzawa
Przemyslaw Ciepiela
Tomasz Baczkowski
Krzysztof Safranow
Pawel Brelik
Publication date: 01-08-2008
Publisher: Springer US
Published in: Journal of Assisted Reproduction and Genetics / Issue 8/2008
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-008-9249-7

At a glance: The STEP trials

Springer Medicine

Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2008

Oral contraceptive pretreatment and half dose of ganirelix does not excessively suppress LH and may be an excellent choice for scheduling IUI cycles

Effects of cryopreservation on sperm parameters and ultrastructural morphology of human spermatozoa

Protective potential of SCF for mice preimplantation embryos cultured in vitro in suboptimal conditions

Interval double transfer improves treatment success in patients with repeated IVF/ET failures

Clinical outcome of magnetic activated cell sorting of non-apoptotic spermatozoa before density gradient centrifugation for assisted reproduction

CYP1A1 and CYP1B1 genetic polymorphisms and uterine leiomyoma risk in Chinese women